SEC Form DEFA14A filed by West Pharmaceutical Services Inc.

$WST
Medical/Dental Instruments
Health Care
Get the next $WST alert in real time by email
DEFA14A 1 tmb-20250320xdefa14a.htm DEFA14A

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934 (Amendment No.           )

Filed by the Registrant   x

Filed by a Party other than the Registrant  ¨

Check the appropriate box:

¨

Preliminary Proxy Statement

¨

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

¨

Definitive Proxy Statement

x

Definitive Additional Materials

¨

Soliciting Material under §240.14a-12

  

 

West Pharmaceutical Services, Inc.

(Name of Registrant as Specified In Its Charter)

 

 

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

x

No fee required.

¨

Fee paid previously with preliminary materials.

¨

Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11


GRAPHIC

Your Vote Counts! WEST PHARMACEUTICAL SERVICES, INC. You invested in WEST PHARMACEUTICAL SERVICES, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the shareholder meeting to be held on May 6, 2025. Vote Virtually at the Meeting* May 6, 2025 9:30 AM EDT Virtually at: www.virtualshareholdermeeting.com/WST2025 *Please check the meeting materials for any special requirements for meeting attendance. Smartphone users Point your camera here and vote without entering a control number For complete information and to vote, visit www.ProxyVote.com Control # V62352-P26361 Get informed before you vote View the Notice and Proxy Statement and Annual Report online OR you can receive a free paper or email copy of the material(s) by requesting prior to April 22, 2025. If you would like to request a copy of the material(s) for this and/or future shareholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. WEST PHARMACEUTICAL SERVICES, INC. C/O BROADRIDGE CORPORATE ISSUER SOLUTIONS P.O. BOX 1342 BRENTWOOD, NY 11717 2025 Annual Meeting Vote by May 5, 2025 11:59 PM EDT. For shares held in a Plan, vote by May 1, 2025 11:59 PM EDT.

GRAPHIC

THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming shareholder meeting. Please follow the instructions on the reverse side to vote these important matters. Vote at www.ProxyVote.com Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. Voting Items Board Recommends V62353-P26361 1. Election of Directors; Nominees: 1a. Mark A. Buthman For 1b. William F. Feehery For 1c. Robert F. Friel For 1d. Eric M. Green For 1e. Janet B. Haugen For 1f. Thomas W. Hofmann For 1g. Molly E. Joseph For 1h. Deborah L. V. Keller For 1i. Myla P. Lai-Goldman For 1j. Stephen H. Lockhart For 1k. Douglas A. Michels For 1l. Paolo Pucci For 2. Advisory vote to approve named executive officer compensation; For 3. Amend and Restate Our Amended and Restated Articles of Incorporation to Add a Right For Shareholders to call a Special Meeting; For 4. Amend and Restate Our 2016 Omnibus Incentive Compensation Plan; and For 5. Ratification of the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for 2025. For NOTE: Such other business as may properly come before the meeting or any adjournment thereof.

Get the next $WST alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$WST

DatePrice TargetRatingAnalyst
3/18/2025$275.00Outperform
Evercore ISI
2/14/2025$250.00Hold → Buy
Deutsche Bank
1/8/2025$400.00Buy
Citigroup
12/13/2024Peer Perform
Wolfe Research
12/12/2024$350.00 → $390.00Neutral → Buy
UBS
2/7/2024$323.00 → $536.00Hold → Buy
Jefferies
6/16/2023$390.00 → $405.00Neutral → Buy
BofA Securities
4/11/2023$330.00 → $400.00Equal-Weight → Overweight
Stephens
More analyst ratings

$WST
Press Releases

Fastest customizable press release news feed in the world

See more
  • West to Participate in Upcoming Investor Conferences

    EXTON, Pa., March 5, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, today announced that it will present at the Barclays 27th Annual Global Healthcare Conference on Wednesday, March 12, 2025 at 11:00 AM ET. It will also present at the KBCM Healthcare Forum on Wednesday, March 19, 2025 at 1:30 PM ET. A live audio webcast of these events will be available in the "Investors" section of the Company's website at www.westpharma.com. Replay of the webcasts will be available for approximat

    $WST
    Medical/Dental Instruments
    Health Care
  • West Announces Second-Quarter Dividend

    EXTON, Pa., Feb. 20, 2025  /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, announced today that the Company's Board of Directors has approved a second-quarter 2025 dividend of $0.21 per share. The dividend will be paid on May 7, 2025, to shareholders of record as of April 30, 2025. About West  West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps

    $WST
    Medical/Dental Instruments
    Health Care
  • West Announces Fourth-Quarter and Full-Year 2024 Results

    - Conference Call Scheduled for 9 a.m. EDT Today - EXTON, Pa., Feb. 13, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST) today announced its financial results for the fourth-quarter and full-year 2024 and introduced 2025 financial guidance. Fourth-Quarter Summary (comparisons to prior-year period) & Full-Year 2025 Guidance Fourth-quarter 2024 net sales of $748.8 million increased 2.3%; organic net sales grew 3.3%.Fourth-quarter 2024 reported-diluted EPS of $1.78 declined 2.7%; fourth-quarter 2024 adjusted-diluted EPS of $1.82 declined 0.5%.For Full-year 2025,

    $WST
    Medical/Dental Instruments
    Health Care

$WST
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$WST
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$WST
SEC Filings

See more

$WST
Leadership Updates

Live Leadership Updates

See more
  • Sotera Health Appoints Karen Flynn to Board of Directors

    CLEVELAND, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Sotera Health Company (NASDAQ:SHC), a leading global provider of mission-critical end-to-end sterilization solutions and lab testing and advisory services for the healthcare industry, announced today it has appointed Karen Flynn as a new independent director to its Board. Ms. Flynn is an accomplished healthcare leader with over 35 years of commercial, operations and general management experience in the pharmaceutical services industry. She most recently served as Interim President of BioModalities at Catalent (NYSE:CTLT), a global provider of development and manufacturing solutions for drugs, biologics, cell and gene therapies and consumer heal

    $CTLT
    $QTRX
    $SHC
    $WST
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials
  • West Announces Executive Leadership Appointments

    EXTON, Pa., May 12, 2022 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, announced today the appointment of West's Chief Financial Officer (CFO) Bernard J. Birkett to a newly combined position of Chief Financial and Operations Officer. In this expanded role, Mr. Birkett will lead our Global Operations and Global Supply Chain. The Company's Senior Vice President, Chief Global Operations and Supply Chain Officer, David Montecalvo has announced his resignation to pursue other interests with a departure of July 2022 to ensure a seamless transition.

    $WST
    Medical/Dental Instruments
    Health Care

$WST
Financials

Live finance-specific insights

See more
  • West Announces Second-Quarter Dividend

    EXTON, Pa., Feb. 20, 2025  /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, announced today that the Company's Board of Directors has approved a second-quarter 2025 dividend of $0.21 per share. The dividend will be paid on May 7, 2025, to shareholders of record as of April 30, 2025. About West  West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps

    $WST
    Medical/Dental Instruments
    Health Care
  • West Announces Fourth-Quarter and Full-Year 2024 Results

    - Conference Call Scheduled for 9 a.m. EDT Today - EXTON, Pa., Feb. 13, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST) today announced its financial results for the fourth-quarter and full-year 2024 and introduced 2025 financial guidance. Fourth-Quarter Summary (comparisons to prior-year period) & Full-Year 2025 Guidance Fourth-quarter 2024 net sales of $748.8 million increased 2.3%; organic net sales grew 3.3%.Fourth-quarter 2024 reported-diluted EPS of $1.78 declined 2.7%; fourth-quarter 2024 adjusted-diluted EPS of $1.82 declined 0.5%.For Full-year 2025,

    $WST
    Medical/Dental Instruments
    Health Care
  • West to Host Fourth-Quarter and Full-Year 2024 Conference Call

    EXTON, Pa., Jan. 30, 2025  /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE:WST),  global leader in innovative solutions for injectable drug administration, today announced that it will release fourth-quarter and full-year 2024 financial results before the market opens on Thursday, February 13, 2025, and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time. The live webcast will be made available via the Company's Investor Relations website or by clicking here. To ask questions on the conference call, participant

    $WST
    Medical/Dental Instruments
    Health Care

$WST
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more